胶质母细胞瘤患者分次腔内放射免疫治疗使用[177Lu]Lu-6A10-Fab片段的首次临床经验:一项先导研究
三名胶质母细胞瘤患者在标准放化疗后疾病稳定,基于同情用药接受分次腔内放射免疫治疗(iRIT),使用靶向肿瘤相关碳酸酐酶XII的[177Lu]Lu-6A10-Fab片段经皮下储液囊注入切除腔。两例完成三周期全程(总活度592 MBq和1228 MBq),一例第二周期后组织学证实肿瘤进展(总活度526 MBq),未观察到相关毒性或不良事件,剂量学未显示危及器官超限。作者认为该疗法在首批个体病例中似乎可行且安全。
要点
- 三例胶质母细胞瘤患者标准治疗后疾病稳定,基于同情用药接受分次iRIT。
- 两例完成三周期(592 MBq和1228 MBq),一例第二周期后组织学证实进展(526 MBq)。
- 未观察到相关毒性或不良事件,剂量学未显示危及器官吸收剂量超上限。
核心结论
- 在首批个体病例中,[177Lu]Lu-6A10-Fab分次iRIT似乎可行且安全,无治疗相关副作用。
- 一项验证性多中心I期试验近期已启动并正在招募。
研究设计与样本
- 先导研究,纳入三例完成标准放化疗后疾病稳定的胶质母细胞瘤患者,基于同情用药接受iRIT。
- 术中植入皮下注射储液囊及导管至切除腔,先用[99mTc]Tc-DTPA行泄漏试验排除泄漏至其他脑室腔隙。
- 每例患者三个月内连续三次给药,分别注入总活度的25%、50%、25%。
- 包含剂量学方案:采血及腹部SPECT/CT,计算骨髓和肾脏作为潜在危及器官的剂量。
主要发现
- 三例患者给予[99mTc]Tc-DTPA后均无相关泄漏。
- 两例完成三个完整iRIT周期,总活度分别为592 MBq和1228 MBq。
- 一例在第二周期后组织学证实肿瘤进展,总活度526 MBq。
- 未观察到相关治疗毒性或不良事件。
- 剂量学未显示危及器官吸收剂量超过剂量上限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with 177Lu-labeled 6A10-Fab fragments targeting tumor-associated carbonic anhydrase XII and injected into the resection cavity offers a novel and promising strategy for improved tumor control. METHODS: Three glioblastoma patients underwent tumor resection followed by standard radio- and chemotherapy. These patients with stable disease following completion of standard therapy underwent iRIT on compassionate grounds. After surgical implantation of a subcutaneous injection reservoir with a catheter into the resection cavity, a leakage test with [99mTc]Tc-DTPA was performed to rule out leakage into other cerebral compartments. IRIT comprised three consecutive applications over three months for each patient, with 25%, 50%, 25% of the total activity injected. A dosimetry protocol was included with blood sampling and SPECT/CT of the abdomen to calculate doses for the bone marrow and kidneys as potential organs at risk. RESULTS: All three patients presented without relevant leakage after application of [99mTc]Tc-DTPA. Two patients underwent three full cycles of iRIT (592 MBq and 1228 MBq total activity). One patient showed histologically proven tumor progression after the second cycle (526 MBq total activity). No relevant therapy-associated toxicities or adverse events were observed. Dosimetry did not reveal absorbed doses above upper dose limits for organs at risk. CONCLUSIONS: In first individual cases, iRIT with [177Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.
引用
- Roll W, Müther M, Böning G, et al. First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study. EJNMMI Res. 2023. PMID: 37665396. doi:10.1186/s13550-023-01029-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。